PapersFlow Research Brief
Polyomavirus and related diseases
Research Guide
What is Polyomavirus and related diseases?
Polyomavirus and related diseases refer to the association of polyomaviruses, particularly Merkel cell polyomavirus and JC virus, with malignancies such as Merkel cell carcinoma and neurological conditions like progressive multifocal leukoencephalopathy in immunocompromised individuals.
The field encompasses 43,333 works examining polyomavirus roles in tumorigenesis and immunosuppression-related pathologies. Key focuses include Merkel cell polyomavirus integration in Merkel cell carcinoma and JC virus reactivation under therapies like natalizumab. Research also addresses viral replication in renal transplant recipients and oncoprotein functions in cancer development.
Topic Hierarchy
Research Sub-Topics
Merkel Cell Polyomavirus
This sub-topic investigates the role of Merkel cell polyomavirus (MCV) in Merkel cell carcinoma oncogenesis, including viral integration, large T antigen expression, and clonal expansion in tumors. Researchers use genomic sequencing, immunohistochemistry, and animal models to elucidate transformation mechanisms.
Progressive Multifocal Leukoencephalopathy
Studies focus on JC virus reactivation causing progressive multifocal leukoencephalopathy (PML) in immunocompromised patients, covering neuropathology, diagnostic imaging, and risk factors like HIV or monoclonal antibodies. Research develops biomarkers, antiviral treatments, and immune reconstitution strategies.
JC Virus
This area examines JC virus prevalence, primary infection, asymptomatic persistence in kidneys, and reactivation triggers under immunosuppression. Molecular epidemiology tracks genotypes, tropism shifts from kidney to brain, and evolutionary dynamics using PCR and phylogenetics.
Viral Oncoproteins
Researchers characterize polyomavirus oncoproteins like large T and small T antigens, their interactions with host p53, Rb pathways, and epigenetic regulators in tumorigenesis. Structural biology and high-throughput screens identify inhibitors for therapeutic intervention.
Natalizumab PML Risk
This sub-topic assesses PML incidence, predictive biomarkers like anti-JCV antibodies, and risk stratification in natalizumab-treated multiple sclerosis patients. Pharmacovigilance studies evaluate switching strategies and incidence modeling post-withdrawal.
Why It Matters
Polyomaviruses contribute to severe diseases in vulnerable populations, such as Merkel cell carcinoma in immunosuppressed patients, where Feng et al. (2008) identified clonal integration of Merkel cell polyomavirus in human Merkel cell carcinoma tumors, establishing its etiologic role. JC virus causes progressive multifocal leukoencephalopathy, a risk heightened by natalizumab therapy, as shown in Polman et al. (2006)'s trial where natalizumab reduced multiple sclerosis relapses but carries this known adverse effect. Immunosuppressive regimens in renal transplantation and cancer immunotherapy exacerbate viral nephropathy and malignancies, with Wanchoo et al. (2017) reviewing adverse renal effects of immune checkpoint inhibitors that intersect with polyomavirus complications in oncology patients.
Reading Guide
Where to Start
"Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma" by Feng et al. (2008), as it provides direct evidence of viral etiology in a key human cancer, making it an accessible entry to polyomavirus-disease links.
Key Papers Explained
"Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma" (Feng et al., 2008) establishes Merkel cell polyomavirus integration, building on earlier work like "T antigen is bound to a host protein in SY40-transformed cells" (Lane and Crawford, 1979) that defined T antigen-host interactions in SV40 models. "Selective extraction of polyoma DNA from infected mouse cell cultures" (Hirt, 1967) provides methodological foundations for viral DNA studies informing these findings. "A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis" (Polman et al., 2006) connects JC virus risks to clinical immunosuppression, extending polyomavirus disease associations.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research emphasizes viral oncoproteins and immunosuppression interactions, as seen in keyword focuses like T antigen mutations and viral nephropathy, though no recent preprints are available.
Papers at a Glance
Frequently Asked Questions
What is the role of Merkel cell polyomavirus in Merkel cell carcinoma?
Clonal integration of Merkel cell polyomavirus occurs in human Merkel cell carcinoma, a rare aggressive skin cancer affecting elderly and immunosuppressed individuals. Feng et al. (2008) detected a fusion transcript of the virus in tumor samples via digital transcriptome subtraction. This finding supports an infectious origin for the malignancy.
How does natalizumab relate to JC virus and progressive multifocal leukoencephalopathy?
Natalizumab, used for relapsing multiple sclerosis, increases risk of progressive multifocal leukoencephalopathy caused by JC virus reactivation in immunocompromised patients. Polman et al. (2006) demonstrated natalizumab reduced disability progression and relapse rates in a randomized trial. Adhesion-molecule inhibition like natalizumab holds therapeutic promise despite this risk.
What are T antigen mutations in polyomaviruses?
T antigen is a viral oncoprotein in polyomaviruses that promotes tumorigenesis. Lane and Crawford (1979) showed T antigen binds to a host protein in SV40-transformed cells. This interaction is central to understanding polyomavirus-driven malignancies.
How do immune checkpoint inhibitors affect polyomavirus-related renal issues?
Immune checkpoint inhibitors like anti-CTLA-4 and anti-PD-1 can lead to adverse renal effects intersecting with polyomavirus nephropathy in transplant recipients. Wanchoo et al. (2017) reviewed these effects in cancer patients. The analysis highlights risks from immunosuppression and viral replication.
What is the evidence for polyomavirus DNA extraction in infected cells?
Selective extraction of polyoma DNA from infected mouse cell cultures enables study of viral genomes. Hirt (1967) developed this method for isolating polyoma DNA. It remains foundational for polyomavirus research.
Open Research Questions
- ? How do mutations in T antigen oncoproteins modulate polyomavirus oncogenicity in human cancers?
- ? What mechanisms underlie JC virus reactivation during natalizumab treatment for multiple sclerosis?
- ? Can virus-like particles derived from polyomaviruses serve as vaccines against related diseases?
- ? What host factors interact with polyomavirus proteins to drive Merkel cell carcinoma progression?
- ? How do immune checkpoint inhibitors influence polyomavirus replication in renal transplant patients?
Recent Trends
The field maintains 43,333 works with sustained interest in polyomavirus links to Merkel cell carcinoma and progressive multifocal leukoencephalopathy, driven by papers like Feng et al. on viral integration (3152 citations) and Polman et al. (2006) on natalizumab risks (3284 citations).
2008No recent preprints or news coverage indicate steady rather than accelerating growth, with growth rate unavailable over 5 years.
Research Polyomavirus and related diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Polyomavirus and related diseases with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers